动脉内[177Lu]Lu-DOTATATE单药治疗难治性脑膜瘤的疗效
本研究为回顾性队列研究,纳入17例局部治疗后难治的WHO 1-3级脑膜瘤患者,至少接受一周期动脉内[177Lu]Lu-DOTATATE治疗。中位随访36个月,6个月无进展生存率65%(95%CI 46-92%),6个月总生存率82%(95%CI 66-100%),疾病控制率53%(95%CI 28-77%),客观缓解率24%(95%CI 7-50%)。结论认为该治疗安全有效,但需前瞻性对照研究验证。
要点
- 动脉内[177Lu]Lu-DOTATATE在难治性脑膜瘤中客观缓解率达24%。
- 6个月无进展生存率65%,6个月总生存率82%。
- 安全事件包括2例3级贫血和1例外周栓塞相关局部坏死。
核心结论
- 在难治性脑膜瘤队列中,动脉内[177Lu]Lu-DOTATATE安全有效,客观缓解率24%,生存数据超过已发表基准。
研究设计与样本
- 回顾性队列研究,纳入17例诊断为难治性脑膜瘤(WHO 1-3级)且至少接受一周期动脉内[177Lu]Lu-DOTATATE的患者。
主要发现
- 中位随访36个月(范围1-57个月),6个月无进展生存率65%(95%CI 46-92%),6个月总生存率82%(95%CI 66-100%)。
- 最佳客观反应中,疾病控制率53%(95%CI 28-77%),客观缓解率24%(95%CI 7-50%)。
- 安全性方面,2例发生3级贫血,1例因外周栓塞导致局部坏死(血管造影干预相关并发症)。
临床怎么用
- 对于局部治疗后难治的脑膜瘤,动脉内[177Lu]Lu-DOTATATE可作为候选治疗选择,需注意贫血和栓塞相关并发症。
局限性
- 回顾性设计、样本量小(17例),需要更大规模前瞻性对照研究比较动脉内与静脉给药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: For meningiomas that are refractory after local treatments, there are no systemic evidence-based therapeutic options to date. In recent years, somatostatin-targeted radionuclide therapy has emerged as a promising new treatment modality. Recent studies have indicated that intra-arterial administration of [177Lu]Lu-DOTATATE may increase the tumor absorbed dose. This study aims to assess the efficacy of intra-arterial [177Lu]Lu-DOTATATE in a cohort of treatment-refractory meningiomas. MATERIALS AND METHODS: Retrospective cohort study including patients diagnosed with treatment-refractory meningioma (WHO grade 1-3), who had received at least one cycle of intra-arterial [177Lu]Lu-DOTATATE. Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included objective response, and safety and toxicity. RESULTS: Seventeen patients with a median follow-up duration of 36 months (range: 1-57 months) were included. Six-month PFS was 65% (95% CI: 46-92%) and 6-month OS was 82% (95% CI: 66-100%). Regarding best objective response, disease control was found in 53% (95% CI: 28-77%); with an objective response rate of 24% (95% CI: 7-50%). In terms of safety, two patients developed grade 3 anemia, while one patient experienced local necrosis as a result of peripheral embolism, a complication related to angiographic intervention. CONCLUSION: In a treatment-refractory meningioma cohort, intra-arterial administration of [177Lu]Lu-DOTATATE is safe and effective, with an objective response rate of 24%, and survival data that exceed published benchmarks. Prospective controlled studies with larger cohorts and extended follow-up are needed, comparing intra-arterial [177Lu]Lu-DOTATATE to (historic) cohorts receiving intravenous administration are needed.
引用
- El Ghalbouni A, Snijders TJ, Amerein A, et al. Efficacy of Intra-arterial [177Lu]Lu-DOTATATE monotherapy for treatment-refractory meningioma. J Neurooncol. 2025. PMID: 41091274. doi:10.1007/s11060-025-05266-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。